GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Labo Euromedis (LTS:0I0L) » Definitions » Debt-to-EBITDA

Labo Euromedis (LTS:0I0L) Debt-to-EBITDA : -1.78 (As of Jun. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Labo Euromedis Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Labo Euromedis's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was €0.01 Mil. Labo Euromedis's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was €11.79 Mil. Labo Euromedis's annualized EBITDA for the quarter that ended in Jun. 2023 was €-6.62 Mil. Labo Euromedis's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2023 was -1.78.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Labo Euromedis's Debt-to-EBITDA or its related term are showing as below:

LTS:0I0L' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -11.65   Med: 2.18   Max: 4.8
Current: 0.42

During the past 14 years, the highest Debt-to-EBITDA Ratio of Labo Euromedis was 4.80. The lowest was -11.65. And the median was 2.18.

LTS:0I0L's Debt-to-EBITDA is ranked better than
72.52% of 433 companies
in the Medical Devices & Instruments industry
Industry Median: 1.26 vs LTS:0I0L: 0.42

Labo Euromedis Debt-to-EBITDA Historical Data

The historical data trend for Labo Euromedis's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Labo Euromedis Debt-to-EBITDA Chart

Labo Euromedis Annual Data
Trend Jul13 Jul14 Jul15 Jul16 Jul17 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -11.65 0.52 3.58 -2.91 0.46

Labo Euromedis Semi-Annual Data
Jul13 Jan14 Jul14 Jan15 Jul15 Jan16 Jul16 Jan17 Jul17 Jan18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.84 -1.94 9.80 -1.78 0.18

Competitive Comparison of Labo Euromedis's Debt-to-EBITDA

For the Medical Devices subindustry, Labo Euromedis's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Labo Euromedis's Debt-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Labo Euromedis's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Labo Euromedis's Debt-to-EBITDA falls into.



Labo Euromedis Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Labo Euromedis's Debt-to-EBITDA for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.003 + 12.835) / -4.419
=-2.91

Labo Euromedis's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.005 + 11.794) / -6.616
=-1.78

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Jun. 2023) EBITDA data.


Labo Euromedis  (LTS:0I0L) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Labo Euromedis Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Labo Euromedis's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Labo Euromedis (LTS:0I0L) Business Description

Traded in Other Exchanges
Address
ZI de la Tuilerie, Neuilly-sous-Clermont, FRA, 60290
Euromedis Groupe is engaged in medical devices. It is engaged in the design, manufacture, rental and export of medical and surgical equipment and products.

Labo Euromedis (LTS:0I0L) Headlines

No Headlines